C2I Alumni, SQZ Biotechnologies, announces $65M investment to push cancer vaccine and cell-squeezing

C2I alumni, SQZ Biotechnologies, announced a $65M investment by Roche to push a cancer vaccine for HPV-positive tumors through phase 1 and expand their signature cell-squeezing technology beyond oncology into infectious diseases. SQZ Biotechnologies signature cancer pipeline is based on a cell therapy platform that squeezes cells and disrupts their membranes to get materials into them. In theory, the treatment would mean engineering the patients' immune cells to present tumor antigens to T cells which would then hunt down cells that express the target antigen. Congratulations! To see the press release: https://lnkd.in/eGEQgqZ

CreaGen launches new hand sanitizer and disinfectant, Coviside, to battle COVID-19

We are committed to doing our part to fight against the COVID-19 pandemic. We are producing a WHO compliant hand sanitizer and disinfectant 100% sourced and manufactured in the USA! Coviside is developed with the highest quality formulation and we are supplying our first responders in the Andover & Woburn area. To purchase our product, visit our website: https://coviside.com

Featured Posts
Recent Posts
Archive
Search By Tags

© 2019 by CreaGen Inc. 

299 Washington St

Woburn, MA 01801 

Tel: 781.938.1122

Fax: 781.938.1123

 

info@creagenbio.com

  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey YouTube Icon
  • Grey Facebook Icon

Business Accelerator | CreaGen C2I | Life Science | Lease Lab Space | Biotech